Analysts take a look at Impax Laboratories, Inc. (NASDAQ:IPXL) having this to say.

August 9, 2018 - By Pearl Odom

Impax Laboratories, Inc. (NASDAQ:IPXL) LogoInvestors sentiment decreased to 1.14 in 2018 Q1. Its down 0.12, from 1.26 in 2017Q4. It is negative, as 21 investors sold Impax Laboratories, Inc. shares while 48 reduced holdings. 25 funds opened positions while 54 raised stakes. 71.42 million shares or 2.34% less from 73.13 million shares in 2017Q4 were reported.
New York State Teachers Retirement Sys, a New York-based fund reported 104,360 shares. Balyasny Asset Limited Liability reported 277,414 shares stake. Wells Fargo & Mn reported 296,179 shares. Gemmer Asset Mngmt Ltd Liability Corporation stated it has 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Parkside Fincl Bank invested in 0% or 70 shares. The New York-based Engineers Gate Manager Lp has invested 0.08% in Impax Laboratories, Inc. (NASDAQ:IPXL). The Missouri-based Argent Cap Mgmt Ltd Llc has invested 0.04% in Impax Laboratories, Inc. (NASDAQ:IPXL). Burt Wealth invested in 0.01% or 506 shares. Gam Holdg Ag reported 44,265 shares. Savings Bank Of Nova Scotia accumulated 212,800 shares. Fisher Asset Mgmt Lc accumulated 1.67M shares. Ls Advsrs Limited Liability Com stated it has 0% in Impax Laboratories, Inc. (NASDAQ:IPXL). Advisory Svcs Networks Limited Liability Company invested in 0% or 90 shares. Suntrust Banks reported 73,321 shares stake. Regions Corporation has 3,837 shares.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Coverage

Among 6 analysts covering Impax Laboratories (NASDAQ:IPXL), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Impax Laboratories had 6 analyst reports since February 27, 2018 according to SRatingsIntel. RBC Capital Markets maintained the shares of IPXL in report on Friday, March 2 with “Hold” rating. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) has “Hold” rating given on Tuesday, February 27 by Susquehanna. The stock has “Hold” rating by BMO Capital Markets on Sunday, April 15. Cowen & Co maintained it with “Hold” rating and $21.0 target in Thursday, March 1 report. Below is a list of Impax Laboratories, Inc. (NASDAQ:IPXL) latest ratings and price target changes.

01/05/2018 Broker: Barclays Capital Rating: Overweight New Target: $27 Initiates Coverage On
15/04/2018 Broker: BMO Capital Markets Rating: Hold New Target: $20.0000 Maintain
07/03/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On
02/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $20.0 Maintain
01/03/2018 Broker: Cowen & Co Rating: Hold New Target: $21.0 Maintain
27/02/2018 Broker: Susquehanna Rating: Hold New Target: $19.0 Maintain

It closed at $18.3 lastly. It is up 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.